Anti-rejection administration after liver transplantation
October 25, 2018 Source: Health News Network
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Recently, a research paper by the Chinese Academy of Engineering and Professor Wang Xuehao from Nanjing Medical University on the new method of postoperative anti-rejection in liver transplantation patients was published in the international academic journal Advanced Materials. The study found a "smart" immune response release drug strategy, designed a "smart" supramolecular hydrogel that automatically releases immunosuppressive drugs. This study provides a new idea for the individualized use of immunosuppressive agents in clinical liver transplant patients. At present, the research team has applied for two patents and is actively promoting the transformation of clinical applications.
Liver transplant patients face rejection after surgery, that is, immune cells (mainly T cells) in the body will attack the implanted organs, and patients need to take immunosuppressive agents for a long time. The first year of liver transplant patients with drug costs up to 200,000 yuan, and then declining year after year, but at least 50,000 yuan a year. Long-term use of immunosuppressive agents is not only expensive, but also susceptible to complications such as cancer, diabetes, hyperlipidemia, hyperuricemia, cardiovascular and cerebrovascular diseases. In addition, some patients are better tolerated, and the rejection is lighter. Taking too many immunosuppressive agents is not only wasteful but also harmful to the body.
How can I take the right amount of medicine based on the patient's own rejection? The Wu Jindao research team of the First Affiliated Hospital of Nanjing Medical University collaborated with the Wang Fuqiang technical team of the Analytical Testing Center of Nanjing Medical University to design a “smart†supramolecular hydrogel. When the rejection is severe, the activity of the phosphorylated kinase in the body is high, the hydrophilicity of the supramolecular hydrogel is enhanced, and the drug is released; when the rejection is light, the activity of the phosphorylated kinase is low, and the supramolecular hydrogel maintains the colloidal property, the drug Stop releasing.
Wang Fuqiang said that this "smart" immune response drug release strategy has two advantages. First, it can be personalized and accurately administered to avoid the side effects of long-term use of immunosuppressants. Second, the composition of hydrogel-forming factors is basically essential amino acids, no side effects, and good biocompatibility. Currently, the method used in the study is to subcutaneously inject 10 microliters to 100 microliters of hydrogel every 15 days. In this way, the patient does not need to take the drug twice a day, and the cost is reduced from about 6,000 yuan per month to 4,000 yuan.
Food Additives,Crab Chitosan,D-Galactose Powder,Calcium Gluconate
SHAANXI HAIBO BIOTECHNOLOGY CO., LTD , https://www.rozenbio.com